#USA #Berwyn #Nordic Pharma #LACRIFILL #Dry Eyes

Nordic Pharma Unveils Breakthrough Dry Eye Treatment

Introduction

Recently, Nordic Pharma, a subsidiary of Nordic Group B.V., garnered attention in the medical community with the inclusion of its innovative product, LACRIFILL® Canalicular Gel, in the new Dry Eye Workshop (DEWS) III report. Published by the Tear Film and Ocular Surface Society (TFOS) in the American Journal of Ophthalmology, this report highlights contemporary therapeutic modalities for managing dry eye symptoms, providing clear guidance to busy ophthalmologists.

Overview of LACRIFILL

LACRIFILL® Canalicular Gel is a groundbreaking treatment designed to alleviate dryness in the eye, which serves as a major concern for millions worldwide. The gel employs a novel formulation that includes crosslinked hyaluronic acid, which has demonstrated positive outcomes in clinical settings. Notably, it addresses symptoms such as corneal staining and reduced tear production effectively.

Research Highlights

The DEWS III report discusses two pivotal studies examining LACRIFILL's efficacy. The first of these found significant improvements in corneal staining and Schirmer test scores, three months post-treatment. In a different comparison involving a commercially available hydrogel canalicular plug, LACRIFILL proved to be extremely safe and well-tolerated. Importantly, patients exhibited statistically significant improvements in both the signs and symptoms of Dry Eye Disease (DED) sustained over six months.

Presentation at WIO Symposium

As part of the ongoing discourse on eye care, Nordic Pharma's research surrounding LACRIFILL will be showcased at the Women in Ophthalmology (WIO) Summer Symposium. A poster presentation titled Evaluation of Lacrimal Punctal Plug Insertion for Dry Eye Relief in Ophthalmology Clinic Patients Using Self-Reported Improvement and OSDI Questionnaires will highlight the findings from Monica Patel and her colleagues. Involving 117 patients, results revealed that 66.25% reported a minimum of 50% symptom improvement one month after the LACRIFILL implant.

Efficacy Across Patient Groups

Dr. Patel, who is also the founder and Medical Director of Clear Vision Ophthalmology, remarked on the study's significance. She emphasized that the evidence gathered reflects LACRIFILL’s efficacy across varied patient demographics, including those with comorbidities like diabetes or thyroid disease. In reviewing both subjective improvements reported by patients and the Ocular Surface Disease Index (OSDI) scores, the data corroborated the positive impact of LACRIFILL on reducing discomfort from dry eyes.

Further Validation from Case Studies

Additional case studies have underscored LACRIFILL’s therapeutic value. One highlighted a patient recovering vision clarity following refractive cataract surgery, showing marked improvement after treatment with LACRIFILL. Another case documented success in managing a patient with Demodex blepharitis infestation and uncontrollable dry eye, with notable enhancements in comfort and reduction in ocular staining after treatment.

Conclusion

With ongoing global discussions surrounding effective management of dry eye symptoms, the versatile applications of LACRIFILL underscore its potential to transform patient outcomes. Nordic Pharma aims to continue sharing research findings with health care providers, reinforcing their commitment to pioneering specialty products that can significantly improve quality of life for those affected by eye conditions. For further details on LACRIFILL Canalicular Gel and ordering information, interested parties can visit the website at lacrifill.com.